<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="487">
  <stage>Registered</stage>
  <submitdate>19/10/2004</submitdate>
  <approvaldate>19/10/2004</approvaldate>
  <nctid>NCT00094497</nctid>
  <trial_identification>
    <studytitle>Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)</studytitle>
    <scientifictitle>First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CO-ACT-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma, Adrenal Cortical</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Etoposide
Treatment: drugs - Doxorubicin
Treatment: drugs - Cisplatin
Treatment: drugs - Streptozotocin
Treatment: drugs - Mitotane

Active Comparator: EDP-M - etopodide, doxorubicin, cisplatin and mitotane

Active Comparator: Sz-M - streptozotocin and mitotane


Treatment: drugs: Etoposide


Treatment: drugs: Doxorubicin


Treatment: drugs: Cisplatin


Treatment: drugs: Streptozotocin


Treatment: drugs: Mitotane


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall Survival - participants who died among those randomized to first-line therapy</outcome>
      <timepoint>every 8 weeks until death up to 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free Survival</outcome>
      <timepoint>every 8 weeks until progression or death up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Quality of Life as Measured by QLQ-C30 - scale ranged from 0 to 100 with higher score meaning greater quality of life</outcome>
      <timepoint>baseline and 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best Overall Response Rate - RECIST 1.0 was used to evaluate response</outcome>
      <timepoint>every 8 weeks up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Disease-free Patients - complete response or disease-free by time of surgery</outcome>
      <timepoint>every 8 weeks until progression (up to 5 years)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed diagnosis of adrenocortical carcinoma

          -  Locally advanced or metastatic disease not amenable to radical surgery resection
             (Stage III-IV)

          -  Radiologically monitorable disease

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  Age =18 years

          -  Adequate bone marrow reserve (neutrophils &gt; 1500/mm3 and platelets &gt; 100,000/mm3)

          -  Effective contraception in pre-menopausal female and male patients

          -  Patient's written informed consent

          -  Ability to comply with the protocol procedures (including availability for follow-up
             visits)

          -  Previous palliative surgery, radiotherapy or radiofrequency ablation is acceptable as
             long as radiologically monitorable disease is verifiable afterwards.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of prior malignancy, except for cured non-melanoma skin cancer, curatively in
             situ cervical carcinoma, or other cancers treated with no evidence of disease for at
             least five years.

          -  Previous cytotoxic chemotherapy for adrenocortical carcinoma

          -  Renal insufficiency (serum creatinine =2 mg/dl or creatinine clearance = 50 ml/min)

          -  Hepatic insufficiency (serum bilirubin =2 x the institutional upper limit of normal
             range and/or serum transaminases = 3 x the institutional upper limit of normal range;
             exception: in patients on mitotane, transaminase levels up to 5 x the institutional
             upper limit of normal range are acceptable)

          -  Pregnancy or breast feeding

          -  Known hypersensitivity to any drug included in the treatment protocol

          -  Presence of active infection

          -  Any other severe clinical condition that in the judgment of the local investigator
             would place the patient at undue risk or interfere with the study completion

          -  Decompensated heart failure (ejection fraction &lt;50%), myocardial infarction or
             revascularization procedure during the last 6 months, unstable angina pectoris, and
             uncontrolled cardiac arrhythmia

          -  Current treatment with other experimental drugs and/or previous participation in
             clinical trials with other experimental agents for adrenocortical carcinoma

          -  Prisoners</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>304</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>SA 5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Duesseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wuerzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Orbassano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Gothenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Linköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Collaborative Group for Adrenocortical Carcinoma Treatment</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>German Federal Ministry of Education and Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether treatment with etoposide, doxorubicin,
      cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane
      (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable
      to complete surgical resection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00094497</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Britt Skogseid, MD</name>
      <address>Uppsala University Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>